At Celgene, we believe patients should have the opportunity, regardless of their location or financial resources, to benefit from advances in prevention, diagnosis and treatment of disease. Corporate responsibility is ingrained in Celgene’s purpose—“to change the course of human health through bold pursuits in science and a promise to always put patients first.”
Investing in advancing medical innovation
With corporate responsibility guiding all business activities, the company is focusing on its mission to discover, develop and deliver to patients innovative medicines that are contributing to human well-being in the areas of haematology, oncology and immunology and inflammation. Over the past five years, almost a third of the company’s revenue has been reinvested into research and development, which is nearly double the industry average. This reinvestment helps support the company’s clinical development programmes.
“What our investment shows is a real commitment to thinking beyond the short term and ensuring sustainable medical innovation to benefit patients today and in the future,” said Zeba Khan, Vice President of Corporate Responsibility at Celgene.
Advancing innovation through transparency
The company’s commitment to medical innovation also extends to responsible and transparent sharing of clinical trial data with patients, healthcare professionals and independent researchers to improve scientific and medical knowledge.
One such example is Celgene’s involvement in Project Data Sphere, an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium which aims to create a platform to share clinical trial data and research findings across academic and biopharmaceutical partners. The initiative is designed with the goal of advancing research to improve the lives of cancer patients and their families around the world.
Environment & Sustainability
Celgene is continuing on its path towards fully understanding the environmental impact and utilising strategies that can help them incorporate technologies, policies and practices to reduce their global carbon footprint. The organisation has implemented strategies focused on energy efficiency, water conservation and waste generation that can benefit the company both environmentally and economically as well as creating a positive result for local communities and people globally.
Since 2009, Celgene Global Health (CGH) has been actively searching for treatments for neglected diseases—such as sleeping sickness, Chagas disease and malaria—that predominantly affect developing nations. Additionally, CGH is identifying key stakeholders and collaborating with partners globally to find innovative solutions for healthcare challenges in the developing world.
Most neglected disease research takes place in academic and non-profit laboratories where access to resources, such as large chemical libraries to screen for potential therapies and platforms for
preclinical and clinical research, is limited. That is where Celgene—with its commitment to improving the lives of patients through innovation—has been helping through public-private partnerships.
Celgene’s commitment to growing its neglected disease collaborations can already be seen. Last year, CGH bolstered its collaboration with the Drugs for Neglected Diseases initiative (DNDi). Together, Celgene and DNDi have been screening therapeutic candidates for neglected disease since 2011. Also in 2014, CGH teamed up with H3-D, South Africa’s first drug discovery and development centre, to identify novel candidates for the treatment of tuberculosis, a disease that still kills more than a million people worldwide annually.
Celgene’s commitment to community
Beyond their job responsibilities, employees have also instinctively ‘done their bit’ as part of all kinds of charitable actions and activities.
In 2014, seven members of staff from the UK office set out to cycle 500km across Malawi to raise money for World Child Cancer (WCC). The team embarked on a grueling four days of intense cycling across tough terrain from Lilongwe to Blantyre. As a result of their fundraising and the time invested for this great cause, the team raised over £45,000 for WCC.
Beyond the UK, Celgene teams globally have also been participating in programmes such as the Leukaemia and Lymphoma Society’s Light The Night Walks and the Pancreatic Cancer Action Network’s Purple Strides campaign, raising funds for disease research.
Celgene Global Health collaborates with partners around the globe to find innovative solutions for healthcare challenges in the developing world. This work is based on the belief that innovative therapies and healthcare partnerships are essential components to long-term progress and prosperity around the globe.
The partnership that Celgene has built with World Child Cancer goes beyond financial donations. For example, the UK and Ireland has been donating soft toys to children at each of the projects that World Child Cancer supports and they have also been involved in a sponsored walk, donated to raffles and taken part in a bike-a-thon. Celgene has been recognised by World Child Cancer as an official corporate sponsor.
“Through its investment in medical innovation, passionate employees and strategic partnerships, Celgene is continuing to demonstrate its commitment to improving the lives of patients through medical innovation,” Khan said.
These examples result from contributions by talented employees who live Celgene’s values and apply them in all that they do for patients and their communities.
Date Preparation: May 2015